| Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study J Rozema, M Hoogendoorn, R Kibbelaar, E van den Berg, N Veeger, ... Blood advances 5 (5), 1344-1351, 2021 | 16 | 2021 |
| A clinical effect of disease-modifying treatment on alloimmunisation in transfused patients with myelodysplastic syndromes: data from a population-based study J Rozema, CL Slim, NJGM Veeger, RE Kibbelaar, H de Wit, EN van Roon, ... Blood Transfusion 20 (1), 18, 2022 | 6 | 2022 |
| Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: a population‐based study J Rozema, EN van Roon, RE Kibbelaar, NJGM Veeger, CL Slim, H de Wit, ... Transfusion 61 (10), 2877-2884, 2021 | 6 | 2021 |
| Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes. MF van Spronsen, TM Westers, H Rozema, GJ Ossenkoppele, ... American journal of hematology 92 (11), E631-E634, 2017 | 4 | 2017 |
| Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes J Rozema, M Hoogendoorn, I Potma, I Ten Seldam, NJGM Veeger, ... EJHaem 3 (3), 775-784, 2022 | 3 | 2022 |
| Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes J Rozema, I van Asten, B Kwant, RE Kibbelaar, NJGM Veeger, H de Wit, ... European Journal of Haematology 109 (6), 772-778, 2022 | 2 | 2022 |
| Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web‐based case vignette questionnaire: The MINDSET study J Rozema, E van Roon, L Vogelzang, R Kibbelaar, N Veeger, ... European journal of haematology 109 (4), 381-387, 2022 | 1 | 2022 |
| Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world J Rozema, J Graafsma, M Hoogendoorn, R Kibbelaar, N Veeger, ... Journal of Geriatric Oncology 14 (2), 101418, 2023 | | 2023 |
| Real-world studies of patients with myelodysplastic syndromes: survival, treatment and outcomes in a population-based setting H Rozema | | 2022 |
| Monitoring of Plasma Ferritin Levels after Blood Transfusions in Patients with Myelodysplastic Syndromes J Rozema, I Van Asten, B Kwant, RE Kibbelaar, NJGM Veeger, H De Wit, ... Blood 138, 1986, 2021 | | 2021 |
| MONITORING OF FERRITIN LEVELS AFTER BLOOD TRANSFUSIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES J Rozema, I Van Asten, B Kwant, R Kibbelaar, N Veeger, H De Wit, ... LEUKEMIA RESEARCH 108, S54-S54, 2021 | | 2021 |
| Topic: AS08-Treatment/AS08j-Supportive care-Iron overload: MONITORING OF FERRITIN LEVELS AFTER BLOOD TRANSFUSIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES J Rozema, I Van Asten, B Kwant, R Kibbelaar, N Veeger, H De Wit, ... Leukemia Research 108, 106681.6, 2021 | | 2021 |
| in Ferritin Monitoring and Initiating Iron Chelation Therapy in Patients with Myelodysplastic Syndromes J Rozema, I van Asten, B Kwant, RE Kibbelaar, NJGM Veeger, H de Wit, ... | | |
